| Study Name | Description | Trial Category Sort ascending | Trial SubCategory |
|---|---|---|---|
| NRG-BR009 | The purpose of this study is treat breast cancer after surgery. You must have estrogen positive breast cancer and an oncotype score ≤25. This study looks at adding chemotherapy to the standard treatment of ovarian function suppression and aromatase inhibitor. | Cancer | Breast |
| NRG-GI004 | The purpose of this study is to look at the effectiveness of Atezolizumab alone or in combination with other chemo regimens. You must be diagnosed with metastatic colorectal cancer with a DNA mismatch repair deficiency and BRAF gene mutation. | Cancer | Metastatic Colorectal |
| NRG-HN005 | The purpose of this study is to determine if a reduced dose of radiation therapy is as effective as the standard dose of radiation. You must be diagnosed with P16-Positive Oropharyngeal cancer. Your smoking history must be <10 pack-years. | Cancer | Oropharyngeal |
| A031902 | The purpose of this study is to evaluate progression free survival and overall survival with the use of enzalutamide and rucaparib vs enzalutamide alone. You must be diagnosed with metastatic castration-resistant prostate cancer. This must be your first treatment for your metastatic cancer. | Cancer | Metastatic Prostate |
| NRG-GU009 | The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with high-risk prostate cancer. | Cancer | Prostate |
| EA3161 | This study is comparing maintenance Nivolumab vs observation in patients with locally advance, intermediate risk HPV Positive oropharynx cancer. | Cancer | Oropharyngeal |
| A081801 (sub study A151216) | The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| NRG-GU010 | The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with unfavorable intermediate risk prostate cancer. | Cancer | Prostate |
| S2013 | The purpose of this study is the look at the side effects of immunotherapy treatment. You must be starting immunotherapy alone not in combination with other treatments. You must have a solid tumor. | Cancer | Solid Tumors |
| NRG-LU002 | The purpose of this study is to compare the effectiveness of chemo alone vs SBRT (stereotactic body radiation therapy) and chemo. You must be diagnosed with metastatic non-small cell lung cancer (NSCLC). You must have already received first line therapy. | Cancer | Metastatic Non-Small Cell Lung |
| A082002 | The purpose of this study is to determine in SBRT (stereotactic body radiation therapy) improves survival in advanced stage NSCLC. You must be diagnosed with stage 3 or 4 Non-Small Cell Lung Cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| NRG-LU008 | The purpose of this study is to compare chemo and radiation followed by immunotherapy vs SBRT (stereotactic body radiation therapy) to primary tumor follwed by chemo and radiation then immunotherapy. You must be diagnosed with Stage 2 or 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| EAY191-E5 | This study is for patients who have a KRAS G12C mutation and advanced/metastatic solid tumors. Your cancer must have progressed on standard of care therapy. You cannot have colorectal cancer or non-small cell lung cancer. | Cancer | Solid Tumors |
| LUNGMAP | This is a screening study to eavluate biomarker-driven therapies and immunotherapies in previously treated Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with Stage 4 or recurrent NSCLC. Tissue is sent for screening and patient can be assigned to a sub study based on mutations found. | Cancer | Metastatic Non-Small Cell Lung |
| NRG-LU007 | This study is comparing effectiveness of atezolizumab alone vs atezolizumab and radiation. You must be diagnosed with extensive stage small cell lung cancer. | Cancer | Small Cell Lung |
| A212102 | This is a study looking at determining effectiveness of a multicancer early dectection blood test. Participants are healthy subjects, those with a known cancer diagnosis, and those with high suspicion of cancer. | Cancer | All tumor types |
| S1803 | The purpose of this study is to compare daratumumab and lenalidomide vs lenalidomide alone for maintenance therapy after stem cell transplant. You must be diagnosed with multiple myeloma. | Cancer | Multiple Myeloma |
| NSABP FB-12 | This is a study for patients diagnosed with Her2 negative breast cancer. It is looking at the effectiveness and safety of doxorubicin plus cyclophosphamide followed by weekly paclitaxel plus trastuzumab and pertuzumab before surgery. | Cancer | Breast |
| NRG-GY019 | The purpose of this study is to compare paclitaxel, carboplatin and maintenace letrozole vs letrozole alone. You must be diagnosed with Stage 2-4 serous ovarian cancer. | Cancer | Serous Ovarian |
| EA2183 | The purpose of this study is to determine if adding radiation to chemo is beneficial. You must be diagnosed with metastatic HER2 negative esophageal and gastric cancer. | Cancer | Esophageal |
| S1900E (LUNGMAP sub study) | The purpose of this study is determine if the use of Sotorasib is effective in patients with previously treated stage 4 or recuurent KRAS G12C mutated non-squamous non-small cell lung cancer (NSCLC). You must be diagnosed with NSCLC with a KRAS G12C mutation. | Cancer | Metastatic Non-Small Cell Lung |
| S1806 | The purpose to this study is to look at the effectiveness of adding atezolizumab to chemo and radiation. You must be diagnosed with muscle invasive bladder cancer. You cannot have already received chemo or radiation. | Cancer | Bladder |
| EA5182 | This study is comparing Osimertinib and Bevacizumab vs Osimertinib alone as first-line treatment for patients with metastatic EGFR mutant Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 3 or 4 NSCLC. | Cancer | Non-Small Cell Lung |
| S1914 | This study is comparing the use of Atezolizumab + SBRT (stereotactic body radiation therapy) vs SBRT Alone in high risk early stage non-small cell lung cancer (NSCLC). You must be diagnosed with stage 1 or 2 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| EA8211 | This study is for patients with renal cell cancer who have a total of 2-5 metastatic lesions. The study is looking at using radiation to the metastatic sites in combination with chemotherapy. | Cancer | Metastatic Renal Cell |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.